About Copmed Pharmaceuticals Private Limited
Data last updated: 31 December 2025
Copmed Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India, a subsidiary of Mankind Pharma Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 13 September 1988, the company has been in operation for over 38 years.
Registered with ROC Delhi under CIN U74899DL1988PTC033151.
Capital: an authorised share capital of ₹2 Cr and a paid-up capital of ₹96 Lakh. It is led by directors including Abhay Kumar Srivastava and Akhlas Ahmed.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: 208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020.
As per the financials filed for FY 2025, the company reported a revenue of ₹437.53 Cr, a decline of 5% compared to the previous year.
The company has a workforce of approximately 349 employees as per the latest available data. It operates as a subsidiary of Mankind Pharma Limited.
The company is associated with 1 brand - Copmed Pharmaceuticals. As per MCA filings, the company has open charges of ₹54.85 Cr and satisfied charges of ₹25.3 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website copmedpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Copmed Pharmaceuticals Private Limited
Copmed Pharmaceuticals Private Limited operates one associated brand: Copmed Pharmaceuticals. These brands represent Copmed Pharmaceuticals Private Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Produces high-quality pharmaceutical products including tablets, capsules, syrups, and injectables. | copmedpharma.com |
Competitors & Alternatives of Copmed Pharmaceuticals Private Limited
Brands and companies operating in the same space as Copmed Pharmaceuticals Private Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Jubilant Life Sciences
|
Company offering a suite of R&D and manufacturing services for small molecules and generics | Noida, India, India | 1978 |
Akums
|
CDMO focusing on spectrum of dosage forms and therapeutic segments | Delhi, India, India | 2004 |
Nectar Lifesciences
|
Cephalosporin APIs and generic formulations are manufactured. | Chandigarh, India, India | 1995 |
Windlas
|
Biopharma regulatory affairs, quality control, and strategy services are provided. | Gurugram, India, India | 2001 |
Unither
|
Contract development and manufacturing organization for proprietary and generic drugs | Paris, France, France | 1993 |
Recipharm
|
Pharmaceutical development and manufacturing services are offered contractually. | Jordbro, Sweden, Sweden | 1995 |
CoreRx
|
CDMO with a focus on early phase drug product development | Clearwater, United States, United States | 2006 |
MedPharm
|
Topical and inhaled drug delivery formulations are developed and manufactured. | Guildford, United Kingdom, United Kingdom | 1998 |
Business Activity of Copmed Pharmaceuticals Private Limited
Copmed Pharmaceuticals Private Limited is engaged in principal business activities including manufacturing and professional, scientific and technical, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, scientific research and development. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Auditor Details of Copmed Pharmaceuticals Private Limited
Copmed Pharmaceuticals Private Limited is audited by S.R. Batliboi & Co. LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| S.R. Batliboi & Co. LLP | blur-value | blur-value | blur-value |
Board of Directors of Copmed Pharmaceuticals Private Limited
Copmed Pharmaceuticals Private Limited is currently managed by 6 directors, with 13 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Abhay Kumar Srivastava
Also directs:
Relax Pharmaceuticals Private Limited, Sirmour Remedies Private Limited, Mankind Medicare Private Limited and 5 more
|
Director | 01 Mar 2021 | 5 Years 4 Months | Current |
|
Akhlas Ahmed
Also directs:
Relax Pharmaceuticals Private Limited, Sirmour Remedies Private Limited, Mankind Medicare Private Limited and 5 more
|
Director | 01 Mar 2021 | 5 Years 4 Months | Current |
| Veer Singh Pal | Director | 31 Jul 2009 | 16 Years 11 Months | Current |
| Jagmohan Sharma | Whole-Time Director | 08 Aug 2024 | 1 Years 11 Months | Current |
|
Bhupendra Kaushik
Also directs:
Relax Pharmaceuticals Private Limited, Bkb & Associates Llp, Alstone Textiles (India) Limited and 4 more
|
Director | 26 Mar 2021 | 5 Years 3 Months | Current |
|
Anju Kumari Jha
Also directs:
Relax Pharmaceuticals Private Limited, Qualitek Starch Private Limited, Mankind Life Sciences Private Limited and 5 more
|
Director | 26 Mar 2021 | 5 Years 3 Months | Current |
Financials of Copmed Pharmaceuticals Private Limited FY 2025 filings available
Copmed Pharmaceuticals Private Limited reported revenue of ₹437.53 Cr (down 5% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Copmed Pharmaceuticals Private Limited
As of FY 2024, Copmed Pharmaceuticals Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Copmed Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Sep 2021 | Others | ₹39.78 Lakh | Open |
| 22 Sep 2021 | Others | ₹45.31 Lakh | Open |
| 30 Sep 2010 | Hdfc Bank Limited | ₹54 Cr | Open |
| 30 Sep 2010 | Hdfc Bank Limited | ₹20 Cr | Satisfied |
| 05 Sep 2009 | Member Secretary | ₹30 Lakh | Satisfied |
Total charge records: 6 View all charges
Employees and EPFO Compliance at Copmed Pharmaceuticals Private Limited
Copmed Pharmaceuticals Private Limited has a workforce of 349 employees as of May 21, 2025.
Employee Count & EPFO Data of Copmed Pharmaceuticals Private Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Copmed Pharmaceuticals Private Limited
GSTIN & GST Filing Data of Copmed Pharmaceuticals Private Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Copmed Pharmaceuticals Private Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Copmed Pharmaceuticals Private Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Copmed Pharmaceuticals Private Limited
MSME Payment Delays by Copmed Pharmaceuticals Private Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Copmed Pharmaceuticals Private Limited
Subsidiaries & Group Companies of Copmed Pharmaceuticals Private Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Copmed Pharmaceuticals Private Limited with ownership details.
MCA Filings & Documents of Copmed Pharmaceuticals Private Limited
MCA Filings & Documents of Copmed Pharmaceuticals Private Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Copmed Pharmaceuticals Private Limited
Frequently Asked Questions about Copmed Pharmaceuticals Private Limited
Copmed Pharmaceuticals Private Limited is an active private limited company in the pharma sector based in New Delhi, Delhi, India. It was incorporated on 13 September 1988 (38+ years old) and is registered under CIN U74899DL1988PTC033151. The company has 349 employees.
Copmed Pharmaceuticals Private Limited reported revenue of ₹437.53 Cr for FY 2025 (down 5.00% YoY).
The current directors of Copmed Pharmaceuticals Private Limited are:
The primary industry of Copmed Pharmaceuticals Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Copmed Pharmaceuticals Private Limited can be reached at the registered office: 208 Okhla Industrial Estate Phase – Iii, New Delhi, Delhi, India – 110020, or through the website copmedpharma.com.
The authorised capital is ₹2 Cr, and the paid-up capital is ₹96 Lakh.